成人急性髓系白血病靶向药物研究进展
Advances in Targeted Drugs for Adult Acute Myeloid Leukemia
DOI: 10.12677/ACM.2023.133561, PDF,   
作者: 刘真娇, 陈 林*：重庆医科大学附属第二医院血液内科，重庆
关键词: AML；靶向治疗；免疫治疗；AML； Targeted Therapy； Immunotherapy
摘要: 急性髓系白血病(acute myeloid leukemia, AML)是成人中最常见的白血病，其预后差、生存期短，具有高度异质性和显著的细胞遗传学特征。近年来随着分子靶向及细胞生物学的发展，在传统化疗方案基础上出现多种新方法可用于该疾病治疗。本综述着重讨论了针对疾病特有的细胞遗传学及复发性基因改变的分子靶向药物治疗(如FLT3抑制剂、IDH抑制剂、BCL-2抑制剂、Hedgehog通路抑制剂等)、新兴免疫疗法(如CAR-T细胞治疗等)，有望进一步扩大AML治疗选择并提高患者生存率。
Abstract: Acute myeloid leukemia (AML) is the most common leukemia in adults, characterized by poor prognosis, short survival, high heterogeneity and significant cytogenetic characteristics. In recent years, with the development of molecular targeting and cell biology, many new methods have ap-peared on the basis of traditional chemotherapy for the treatment of this disease. This review fo-cuses on molecular targeted drug therapies targeting disease-specific cytogenetics and recurrent gene changes (e.g., FLT3 inhibitors, IDH inhibitors, BCL-2 inhibitors, Hedgehog pathway inhibitors, etc.), emerging immunotherapies (e.g., CAR T cell therapy). It is expected to further expand treat-ment options for AML and improve patient survival.
文章引用：刘真娇, 陈林. 成人急性髓系白血病靶向药物研究进展[J]. 临床医学进展, 2023, 13(3): 3911-3918. https://doi.org/10.12677/ACM.2023.133561

参考文献

[1] Newell, L. and Cook, R. (2021) Advances in Acute Myeloid Leukemia. BMJ (Clinical Research ed), 375, 2026. [Google Scholar] [CrossRef] [PubMed]
[2] Kirtonia, A., Pandya, G., Sethi, G., et al. (2020) A Comprehensive Review of Genetic Alterations and Molecular Targeted Therapies for the Implementation of Personalized Medicine in Acute Myeloid Leukemia. Journal of Molecular Medicine (Berlin, Germany), 98, 1069-1091. [Google Scholar] [CrossRef] [PubMed]
[3] Lancet, J., Uy, G., Newell, L., et al. (2021) CPX-351 versus 7+3 Cytarabine and Daunorubicin Chemotherapy in Older Adults with Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia: 5-Year Results of a Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Haematology, 8, e481-e491. [Google Scholar] [CrossRef] 
[4] Swaminathan, M. and Wang, E. (2020) Novel Therapies for AML: A Round-Up for Clinicians. Expert Review of Clinical Pharmacology, 13, 1389-1400. [Google Scholar] [CrossRef] [PubMed]
[5] Lancet, J., Uy, G., Cortes, J., et al. (2018) CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection versus Conventional Cytarabine plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36, 2684-2692. [Google Scholar] [CrossRef] 
[6] Roboz, G., Montesinos, P., Selleslag, D., et al. (2016) Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid Leukemia. Future Oncology (London, England), 12, 293-302. [Google Scholar] [CrossRef] [PubMed]
[7] De Lima, M., Roboz, G., Platzbecker, U., et al. (2021) AML and the Art of Remission Maintenance. Blood Reviews, 49, Article ID: 100829. [Google Scholar] [CrossRef] [PubMed]
[8] Leopold, L. and Willemze, R. (2002) The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature. Leukemia & Lymphoma, 43, 1715-1727. [Google Scholar] [CrossRef] [PubMed]
[9] Wei, A., Döhner, H., Pocock, C., et al. (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. The New England Journal of Medicine, 383, 2526-2537. [Google Scholar] [CrossRef] 
[10] Gottardi, M., Simonetti, G., Sperotto, A., et al. (2021) Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers, 13, 4566. [Google Scholar] [CrossRef] [PubMed]
[11] Kantarjian, H., Kadia, T., Dinardo, C., et al. (2021) Acute Myeloid Leukemia: Current Progress and Future Directions. Blood Cancer Journal, 11, 41. [Google Scholar] [CrossRef] [PubMed]
[12] Short, N., Kantarjian, H., Ravandi, F., et al. (2019) Emerging Treatment Paradigms with FLT3 Inhibitors in Acute Myeloid Leukemia. Therapeutic Advances in Hematology, 10, 1-18. [Google Scholar] [CrossRef] [PubMed]
[13] Yazdandoust, E., Sadeghian, M., Shams, S., et al. (2022) FLT3-ITD Evaluation of Mutations and Gene Expression in AML Patients. Iranian Journal of Pathology, 17, 419-426. [Google Scholar] [CrossRef] [PubMed]
[14] Padmakumar, D., Chandraprabha, V., Gopinath, P., et al. (2021) A Concise Review on the Molecular Genetics of Acute Myeloid Leukemia. Leukemia Research, 111, Article ID: 106727. [Google Scholar] [CrossRef] [PubMed]
[15] Tecik, M. and Adan, A. (2022) Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. OncoTargets and Therapy, 15, 1449-1478. [Google Scholar] [CrossRef] 
[16] Nuhoğlu Kantarci, E. and Eşkazan, A. (2022) Gilteritinib in the Management of Acute Myeloid Leukemia: Current Evidence and Future Directions. Leukemia Research, 114, Article ID: 106808. [Google Scholar] [CrossRef] [PubMed]
[17] Stanchina, M., Soong, D., et al. (2020) Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. Cancers, 12, 3225. [Google Scholar] [CrossRef] [PubMed]
[18] Kantarjian, H., Short, N., Dinardo, C., et al. (2021) Harnessing the Benefits of Available Targeted Therapies in Acute Myeloid Leukaemia. The Lancet Haematology, 8, e922-e933. [Google Scholar] [CrossRef] 
[19] Short, N., Konopleva, M., Kadia, T., et al. (2020) Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery, 10, 506-525. [Google Scholar] [CrossRef] 
[20] Kucukyurt, S. and Eskazan, A. (2019) New Drugs Approved for Acute Myeloid Leukaemia in 2018. British Journal of Clinical Pharmacology, 85, 2689-2693. [Google Scholar] [CrossRef] [PubMed]
[21] Bohl, S., Bullinger, L. and Rücker, F. (2019) New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. International Journal of Molecular Sciences, 20, 1983. [Google Scholar] [CrossRef] [PubMed]
[22] Amaya, M. and Pollyea, D. (2018) Targeting the IDH2 Pathway in Acute Myeloid Leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Re-search, 24, 4931-4936. [Google Scholar] [CrossRef] 
[23] Tian, W., Zhang, W., Wang, Y., et al. (2022) Recent Ad-vances of IDH1 Mutant Inhibitor in Cancer Therapy. Frontiers in Pharmacology, 13, Article ID: 982424. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, X. and Gong, Y. (2019) Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia. Biomarker Research, 7, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[25] Stemer, G., Rowe, J. and Ofran, Y. (2021) Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. Blood and Lymphatic Cancer: Targets and Therapy, 11, 41-54. [Google Scholar] [CrossRef] 
[26] Abou Dalle, I. and Dinardo, C. (2018) The Role of Enasidenib in the Treatment of Mutant IDH2 Acute Myeloid Leukemia. Therapeutic Advances in Hematology, 9, 163-173. [Google Scholar] [CrossRef] [PubMed]
[27] Kayser, S. and Levis, M. (2023) The Clinical Impact of the Mo-lecular Landscape of Acute Myeloid Leukemia. Haematologica, 108, 308-320. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, H. (2021) Emerging Agents and Regimens for AML. Journal of Hematology & Oncology, 14, 49. [Google Scholar] [CrossRef] [PubMed]
[29] Michelozzi, I., Kirtsios, E. and Giustacchini, A. (2021) Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. Cancers, 13, 2816. [Google Scholar] [CrossRef] [PubMed]
[30] Lainez-González, D., Serrano-López, J. and Alonso-Domínguez, J. (2021) Understanding the Hedgehog Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Necessary Step toward a Cure. Biology, 10, 255. [Google Scholar] [CrossRef] [PubMed]
[31] Terao, T. and Minami, Y. (2019) Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment. Cells, 8, 312. [Google Scholar] [CrossRef] [PubMed]
[32] Iyer, S., Stanchina, M., Bradley, T., et al. (2022) Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. Cancer Management and Research, 14, 2267-2272. [Google Scholar] [CrossRef] 
[33] Halik, A., Arends, C., Bullinger, L., et al. (2022) Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. Cancers, 14, 1689. [Google Scholar] [CrossRef] [PubMed]
[34] Kayser, S. and Levis, M. (2022) Updates on Targeted Therapies for Acute Myeloid Leukaemia. British Journal of Haematology, 196, 316-328. [Google Scholar] [CrossRef] [PubMed]
[35] Ishii, H. and Yano, S. (2022) New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers, 14, 2806. [Google Scholar] [CrossRef] [PubMed]
[36] Al-Haideri, M., Tondok, S., Safa, S., et al. (2022) CAR-T Cell Combination Therapy: The Next Revolution in Cancer Treatment. Cancer Cell International, 22, 365. [Google Scholar] [CrossRef] [PubMed]
[37] Schorr, C. and Perna, F. (2022) Targets for Chimeric Antigen Receptor T-Cell Therapy of Acute Myeloid Leukemia. Frontiers in Immunology, 13, Article ID: 1085978. [Google Scholar] [CrossRef] [PubMed]
[38] Zhang, X., Zhu, L., Zhang, H., et al. (2022) CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in Immunology, 13, Article ID: 927153. [Google Scholar] [CrossRef] [PubMed]

为你推荐